Sun Pharmaceutical Industries Ltd (SUNPHARMA)
₹1,777.70
Mkt cap
₹4.27L Cr
P/E ratio
34.70
P/B
4.78
Div yield
0.90%
ROE
16.00%
ROCE
20.50%
EPS (TTM)
₹51.23
Book value
₹372
52W range
1,584–2,047
Sector
Healthcare
Price history
Previous close
Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market. [1] It is the largest pharmaceutical company in India. [2]
NSE SUNPHARMABSE 524715
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−13.15% from high₹1,778
₹1,584+12.25% from low₹2,047
Current
₹1,777.70
Prev close
₹1,761.00
Day
+0.95%
Price performance
1D
+0.95%
1W
+1.70%
1M
−4.68%
3M
−11.16%
6M
−0.06%
1Y
+5.20%
YTD
+2.88%
Financials
Revenue, profit & margin
P/E ratio
34.7×
SUNPHARMA is 1% above the sector median of 34.4×
SUNPHARMA34.7×
Sector median34.4×
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 12,192 | 12,381 | 11,983 | 12,653 | 13,291 | 13,675 | 12,959 | 13,851 | 14,478 | 15,521 | 14,612 | 15,300 | 16,199 | |
| Expenses | 9,013 | 8,904 | 8,948 | 9,045 | 9,352 | 9,666 | 9,243 | 9,550 | 9,951 | 10,572 | 10,658 | 10,882 | 11,455 | |
| Operating Profit | 3,179 | 3,477 | 3,035 | 3,608 | 3,939 | 4,009 | 3,716 | 4,302 | 4,527 | 4,948 | 3,954 | 4,418 | 4,744 | |
| OPM % | 26% | 28% | 25% | 29% | 30% | 29% | 29% | 31% | 31% | 32% | 27% | 29% | 29% | |
| Other Income | 294 | 180 | 504 | 533 | 354 | 149 | 251 | -354 | 470 | 89 | 458 | 520 | -752 | |
| Interest | 49 | 35 | 74 | 62 | 69 | 52 | 49 | 75 | 100 | 78 | 86 | 100 | 75 | |
| Depreciation | 633 | 622 | 650 | 655 | 626 | 631 | 664 | 701 | 730 | 732 | 775 | 739 | 758 | |
| Profit before tax | 2,791 | 3,000 | 2,816 | 3,424 | 3,598 | 3,476 | 3,254 | 3,173 | 4,168 | 4,227 | 3,551 | 4,099 | 3,159 | |
| Tax % | 14% | 14% | 5% | 16% | 16% | 16% | 34% | 27% | 25% | 20% | 23% | 29% | 37% | |
| Net Profit | 2,385 | 2,561 | 2,659 | 2,861 | 3,037 | 2,913 | 2,154 | 2,293 | 3,125 | 3,381 | 2,710 | 2,901 | 1,995 | |
| EPS in Rs | 9.90 | 10.52 | 11.06 | 11.82 | 12.67 | 12.10 | 8.96 | 9.50 | 13.00 | 14.04 | 11.31 | 12.06 | 8.29 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.12% · closed higher next day 28 of last 61
| Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | Q2FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 31 Jan '24◦ | 22 May '24◦ | 1 Aug '24◦ | 28 Oct '24◦ | 31 Jan '25◦ | 22 May '25◦ | 31 Jul '25 | 5 Nov '25◦ | 31 Jan '26◦ | 22 May '26 | 31 Jul '26◦ | 30 Oct '26◦ |
| Earnings day | −0.74% | −2.87% | +0.96% | −1.64% | −0.10% | −2.04% | −1.56% | −0.24% | +2.04% | −2.47% | −1.36% | — |
| +1 day | −0.13% | −3.42% | +0.30% | −2.67% | −0.19% | −2.48% | −6.00% | +0.08% | +6.69% | −2.68% | −1.33% | — |
| +5 days | +5.72% | −5.21% | +1.17% | −3.97% | +0.34% | −2.39% | −7.81% | +2.80% | +6.85% | −5.01% | −2.32% | — |
| +15 days | +9.84% | −1.85% | +3.34% | −5.65% | −5.75% | −1.80% | −5.31% | +7.12% | +8.59% | −4.51% | −4.04% | — |
| +30 days | +9.15% | +1.89% | +8.61% | −4.70% | +0.22% | −2.47% | −7.60% | +3.31% | +12.48% | +0.64% | −7.81% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 7 Jul '26 | 7 Jul '26 |
Shareholding
as of Sep 202652.68%Promoter
Promoters52.68%1.80
FIIs14.36%0.18
DIIs22.27%0.21
Public10.70%1.89
Government0.00%0.11
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +24.68% | 175 | +19.54% | 15.12% |
Filings
Annual reports15
Concall transcripts56
RECOct 2026PPTSep 2026TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026PPTDec 2025TranscriptNov 2025RECNov 2025TranscriptSep 2025PPTSep 2025RECSep 2025PPTJul 2025TranscriptMay 2025RECMay 2025TranscriptMar 2025PPTMar 2025RECJan 2025
Credit ratings6
Announcements5
Completion And Results Of Postal Ballot Dated 01 October 2026 31 OctAnnouncement under Regulation 30 (LODR)-Newspaper Publication 31 Oct - Newspaper publication for unaudited financial results for the quarter and half year ended 30 September 2026Q2FY27 -Investor Call Audio Recording 30 Oct - FY27 Q2 earnings call audio recording posted on website on 30 October 2026.Appointment Of Statutory Auditors Pursuant To Mandatory Auditor Rotation 30 Oct - Board approved Deloitte Haskins & Sells LLP as statutory auditorsAGM 2026-27 for five years.Unaudited Financial Results For The Quarter And Half Year Ended 30 September 2026 30 Oct - Sun Pharma approved Q2 FY27 results; recorded Rs9,226.7 million antitrust settlement charge and Organon acquisition costs.